Term | Mean estimate (std dev; subject std dev) | 95% CI | Marginal utilitiy | LR Chi-square | DF | P-value |
---|---|---|---|---|---|---|
Vaccine effectiveness | ||||||
50% | −0.755 (0.039; 0.323) | [−0.833; − 0.682] | −0.7551 | 383.159 | 1 | <.0001 |
90% | 0.755 (0.036; 0.293) | [0.685; 0.825] | 0.7551 | |||
Burden of disease | ||||||
Rare&mild | −0.764 (0.080; 0.225) | [− 0.953; − 0.632] | −0.7642 | 308.482 | 3 | <.0001 |
Common&mild | −0.753 (0.079; 0.204) | [− 0.900; − 0.595] | −0.7533 | |||
Rare&severe | 0.351 (0.073; 0.144) | [0.201; 0.497] | 0.3511 | |||
Common&severe | 1.166 (0.076; 0.180) | [1.018; 1.315] | 1.1664 | |||
Mild VRSE | ||||||
Common | −0.210 (0.027; 0.102) | [− 0.264; − 0.159] | −0.2103 | 44.657 | 1 | <.0001 |
Rare | 0.210 (0.025; 0.106) | [0.160; 0.260] | 0.2103 | |||
Accessibility | ||||||
Co-payment prescription | −0.608 (0.041; 0.240) | [− 0.691; − 0.533] | −0.6085 | 288.679 | 1 | <.0001 |
Free accessible | 0.608 (0.044; 0.242) | [0.522; 0.695] | 0.6085 | |||
Local coverage (×10%) | 0.054 (0.012; 0.122) | [0.031; 0.078] | 0.0538 | 15.09 | 1 | 0.0001 |
Global coverage (× 10%) | 0.125 (0.013; 0.160) | [0.101; 0.153] | 0.1247 | 79.101 | 1 | <.0001 |
Burden of disease*Educational level | ||||||
Rare&mild*Low | 0.503 (0.134; 0.247) | [0.254; 0.789] | −0.2617 | 38.004 | 6 | <.0001 |
Rare&mild*Mid | −0.099 (0.108; 0.283) | [− 0.291; 0.169] | −0.8635 | |||
Rare&mild*High | −0.403 (0.082; 0.182) | [−0.563; − 0.243] | −1.1675 | |||
Common&mild*Low | 0.196 (0.132; 0.275) | [−0.046; 0.451] | −0.5572 | |||
Common&mild*Mid | −0.005 (0.098; 0.246) | [−0.195; 0.174] | −0.7586 | |||
Common&mild*High | −0.191 (0.094; 0.242) | [−0.375; − 0.006] | −0.9441 | |||
Rare&severe*Low | −0.174 (0.092; 0.180) | [−0.365; − 0.014] | 0.1774 | |||
Rare&severe*Mid | 0.182 (0.071; 0.134) | [0.053; 0.316] | 0.5332 | |||
Rare&severe*High | −0.008 (0.091; 0.161) | [−0.186; 0.170] | 0.3427 | |||
Common&severe*Low | −0.525 (0.094; 0.198) | [− 0.708; − 0.341] | 0.6415 | |||
Common&severe*Mid | −0.078 (0.079; 0.167) | [−0.232; 0.077] | 1.0888 | |||
Common&severe*High | 0.602 (0.093; 0.200) | [0.419; 0.785] | 1.7688 | |||
Burden of disease*Being target group for influenza vaccination | ||||||
Rare&mild*Yes | 0.216 (0.067; 0.190) | [0.093; 0.359] | −0.5482 | 30.472 | 3 | <.0001 |
Common&mild*Yes | 0.179 (0.072; 0.203) | [0.034; 0.313] | −0.5742 | |||
Rare&severe*Yes | −0.087 (0.063; 0.133) | [−0.217; 0.040] | 0.2638 | |||
Common&severe*Yes | −0.308 (0.063; 0.149) | [−0.431; −0.184] | 0.8586 | |||
Rare&mild*No | −0.216 (0.067; 0.145) | [−0.348; −0.084] | −0.9802 | |||
Common&mild*No | −0.179 (0.074; 0.187) | [−0.323; −0.035] | −0.9324 | |||
Rare&severe*No | 0.087 (0.062; 0.116) | [−0.034; 0.209] | 0.4384 | |||
Common&severe*No | 0.308 (0.060; 0.132) | [0.191; 0.425] | 1.4742 | |||
Accessibility*Risk perception Low vs High | ||||||
Co-payment*Low | 0.158 (0.037; 0.256) | [0.091; 0.233] | −0.4500 | 18.311 | 1 | <.0001 |
Co-payment*High | −0.158 (0.037; 0.272) | [−0.231; −0.085] | −0.7669 | |||
Free*Low | −0.158 (0.043; 0.228) | [−0.242; −0.074] | 0.4500 | |||
Free*High | 0.158 (0.037; 0.253) | [0.087; 0.230] | 0.7669 |